[Moreover, we need to understand] the underlying pathology of the individual subtypes; for example, PEComa is a subtype that is seen in the uterus and is an entity that doesn’t respond to conventional cytotoxic chemotherapy. It does, however, respond to mTOR inhibition and there is an ongoing multicenter phase II study looking at a second-generation mTOR inhibitor intravenously as part of a registrational study. If successful, we may have a therapy specifically for PEComas, which would then be relevant for PEComas that start in the uterus.
Is there anything else you would like to emphasize?
The only thing I would recommend is that if there is a suspicion for a sarcoma, patients should be seen and managed in centers with expertise. We know that patients who are seen in academic centers have better outcomes and have access to multidisciplinary approaches, which can result in better outcomes for our patients.